Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hylo Grev
- Development stage
- Unknown
- Lead developer
- Grevis Pharma
- Administration
- Ophthalmic
01
Overview
Hylo Grev is a topical ophthalmic lubricant developed and marketed by Grevis Pharmaceuticals in India. Its active ingredient is sodium hyaluronate (0.1% w/v), a naturally occurring biopolymer that acts as a viscoelastic lubricant. The product is indicated for the treatment of dry eye syndrome (keratoconjunctivitis sicca) and ocular surface lubrication. It works by forming a stable, long-lasting, and moisture-retaining protective layer over the ocular surface, mimicking the function of natural tears without binding to a specific molecular receptor. The formulation is typically supplied as eye drops in a 10ml bottle and may contain sodium perborate as a preservative to maintain sterility.
- Brand names
- Hylo Grev
- Other names
- Hylo-Grev
Beyond the preview
Go deeper on Hylo Grev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hylo Grev.